drugset / Trial / NCT06183008
IVIG in Painful Sensory Neuropathy
Phase 4
Not yet recruiting
20 enrolled
Sorlandet Hospital HF
Oslo University Hospital · collabUniversity Hospital of North Norway · collabUniversity Hospital of Saint-Etienne · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The goal of this clinical trial is to assess effect of Intravenous immunoglobulins (antibodies) as compared to Placebo, on pain intensity in patients from 18-65 years with painful sensory neuropathy without a known cause. Effect of the treatment will be recorded by the patient in a digital diary.
Timeline
- Start
- 2024-02
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 2 g/kg | Intravenous |